Pacemaker-related Tricuspid Regurgitation Progression and Long-term Outcomes

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHaiyan Wang

About this trial

Tricuspid regurgitation (TR) is a common complication following cardiac implantable electronic device (CIED) implantation, with severe TR being associated with increased rates of heart failure hospitalization and all-cause mortality, significantly impairing patients' quality of life. With technological advancements, physiological pacing modalities have demonstrated superior clinical efficacy and safety profiles compared to conventional pacing methods.

This study aims to evaluate predictors of adverse outcomes and TR progression in CIED recipients under different pacing modalities, thereby providing clinical guidance for high-risk patients.

Eligibility criteria

Qualifiers

Adult patients

Patients with an implantable electronic heart device (CIEDs)

The patient underwent pacemaker implantation at Qianfoshan Hospital between 2015 and 2025

Disqualifiers

Patients with severe tricuspid regurgitation or those who have undergone tricuspid valve surgery or interventional treatment prior to pacemaker implantation

Patients with severe valvular heart disease, congenital heart disease, or arrhythmias

Patients with single-chamber pacemakers or poor images

Trial design

Treatments tested in this trial

  • Pacemaker implantation

Treatment groups

200 Participants
are divided into 5 treatment groups

Sponsors and collaborators

Haiyan Wang

Lead sponsor

Qianfoshan Hospital

Sponsor institution